secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vera Therapeutics, Inc. (VERA)
CIK:        0001831828
Form:       8-K
Filed at:   2023-01-30T23:59:59+00:00
Accession:  0001193125-23-018203
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vera Therapeutics announces positive per-protocol analysis from Phase 2b ORIGIN trial of atacicept in IgA nephropathy
--------------------------------------------------------------------------------

- At Week 24, atacicept 150 mg achieved 41% mean reduction in proteinuria and 34% delta vs placebo (p=0.025).
- At Week 36 interim, atacicept 150 mg showed 47% mean reduction from baseline and 48% delta vs placebo.
- Serious treatment-emergent AEs occurred in 2% of atacicept patients vs 9% in placebo; discontinuation rate 1%.
- Company plans to advance atacicept into pivotal Phase 3 in first half of 2023, after FDA discussions.
- Prespecified per-protocol analysis excluded 14 patients with protocol violations identified by blinded CRO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831828/000119312523018203/0001193125-23-018203-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831828/000119312523018203/d381437d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-018203

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer